Cyclerion Therapeutics Inc Total Assets
Cyclerion Therapeutics Inc total assets. Based on the latest financial reports, Cyclerion Therapeutics Inc (CYCN) holds total assets worth $6.93 Million USD as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see market value of Cyclerion Therapeutics Inc for the company's overall valuation and market capitalisation.
Total Assets of Cyclerion Therapeutics Inc (2016–2025)
Total assets of Cyclerion Therapeutics Inc from 2016 to 2025. This chart illustrates how Cyclerion Therapeutics Inc's total assets have evolved over time, based on quarterly financial data. See CYCN live share price for real-time trading data and today's change.
Cyclerion Therapeutics Inc - Asset Composition Analysis
Cyclerion Therapeutics Inc Total Assets Breakdown (December 2025)
Cyclerion Therapeutics Inc total assets breakdown as of December 2025. Cyclerion Therapeutics Inc's total assets of $6.93 Million consist of 46.4% current assets and 53.6% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 32.5% |
| Accounts Receivable | $1.00 Million | 10.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2016–2025)
This chart illustrates how Cyclerion Therapeutics Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore Cyclerion Therapeutics Inc (CYCN) working capital ratio to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Cyclerion Therapeutics Inc's current assets represent 46.4% of total assets in 2025, an increase from 7.1% in 2016.
- Cash Position: Cash and equivalents constituted 32.5% of total assets in 2025, up from 0.0% in 2016.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2016.
- Asset Diversification: The largest asset category is accounts receivable at 10.0% of total assets.
Cyclerion Therapeutics Inc Competitors by Total Assets
Key competitors of Cyclerion Therapeutics Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Hyloris Developmentsen Sa
BR:HYL
|
Belgium | €37.05 Million |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $11.72 Billion |
|
Oruka Therapeutics, Inc.
NASDAQ:ORKA
|
USA | $1.14 Billion |
|
Gempharmatech Co. Ltd. A
SHG:688046
|
China | CN¥2.80 Billion |
|
Vor Biopharma Inc
NASDAQ:VOR
|
USA | $481.05 Million |
|
Inventiva S.A
PA:IVA
|
France | €249.51 Million |
|
Sunmax Biotechnology Co Ltd
TWO:4728
|
Taiwan | NT$1.90 Billion |
|
Apnimed, Inc. Common Stock
NASDAQ:APMD
|
USA | $342.63 Million |
Cyclerion Therapeutics Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.82 | 5.03 | 5.61 |
| Quick Ratio | 0.82 | 5.03 | 5.56 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $-329.00K | $3.22 Million | $52.33 Million |
Cyclerion Therapeutics Inc - Advanced Valuation Insights
This section examines the relationship between Cyclerion Therapeutics Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 3.87 |
| Latest Market Cap to Assets Ratio | 0.23 |
| Asset Growth Rate (YoY) | 4.3% |
| Total Assets | $9.98 Million |
| Market Capitalization | $2.25 Million USD |
Valuation Analysis
Below Book Valuation: The market values Cyclerion Therapeutics Inc's assets below their book value (0.23x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Cyclerion Therapeutics Inc's assets grew by 4.3% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Cyclerion Therapeutics Inc (2016–2025)
The table below shows the annual total assets of Cyclerion Therapeutics Inc from 2016 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $9.98 Million | +4.28% |
| 2024-12-31 | $9.57 Million | -28.41% |
| 2023-12-31 | $13.37 Million | -26.02% |
| 2022-12-31 | $18.08 Million | -69.53% |
| 2021-12-31 | $59.33 Million | -48.58% |
| 2020-12-31 | $115.38 Million | -38.13% |
| 2019-12-31 | $186.48 Million | +2419.63% |
| 2018-12-31 | $7.40 Million | +35.30% |
| 2017-12-31 | $5.47 Million | +41.16% |
| 2016-12-31 | $3.88 Million | -- |
About Cyclerion Therapeutics Inc
As of September 8, 2026, Cyclerion Therapeutics, Inc. was acquired by Korsana Biosciences, Inc. in a reverse merger transaction. Cyclerion Therapeutics, Inc., a biopharmaceutical company, engages in the development of treatments for serious diseases serious diseases with novel sGC stimulators in both the central nervous system (CNS) and the periphery. The company is developing Olinciguat, an oral… Read more